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Elevated serum lipids are linked to cardiovascular diseases calling for effective therapeutic means to reduce
particularly LDL-cholesterol (LDL-C) levels. Plant stanols reduce levels of LDL-C by partly blocking cholesterol
absorption. Accordingly the consumption of foods with added plant stanols, typically esterified with vegetable oil
fatty acids in commercial food products, are recommended for lowering serum cholesterol levels. A daily intake of
1.5 to 2.4 g of plant stanols has been scientifically evaluated to lower LDL-C by 7 to 10% in different populations,
ages and with different diseases. Based on earlier studies, a general understanding is that no further reduction may
be achieved in intakes in excess of approximately 2.5 g/day. Recent studies however suggest that plant stanols
show a continuous dose–response effect in serum LDL-C lowering. This review discusses the evidence for a
dose-effect relationship between plant stanol ester consumption and reduction of LDL-C concentrations with daily
intakes of plant stanols of 4 g/day or more. We identified five such studies and the overall data demonstrate a
linear dose-effect relationship with the most pertinent LDL-Cholesterol lowering outcome, 18%, achieved by a daily
intake of 9 to 10 g of plant stanols. Along with reduction in LDL-C, the studies demonstrated a decrease in
cholesterol absorption markers, the serum plant sterol to cholesterol ratios, by increasing the dose of plant stanol
intake. None of the studies with daily intakes up to 10 g of plant stanols reported adverse clinical or biochemical
effects from plant stanols. In a like manner, the magnitude of decrease in serum antioxidant vitamins was not
related to the dose of plant stanols consumed and the differences between plant stanol ester consumers and
controls were minor and insignificant or nonexisting. Consumption of plant stanols in high doses is feasible as a
range of food products are commercially available for consumption including spreads and yoghurt type drinks. In
conclusion, a dose-effect relationship of plant stanols in higher doses than currently recommended has been
demonstrated by recent clinical studies and a meta-analysis. Further studies are called for to provide confirmatory
evidence amenable for new health claim applications and dietary recommendations.
Keywords: Plant stanols, Plant stanol ester, Phytosterol, LDL cholesterol, Dose–responseIntroduction
Reduction of serum cholesterol and particularly LDL-
cholesterol (LDL-C) is important because high levels are
associated with an increased risk of atherosclerosis and
coronary heart disease [1,2]. Preventive life-style related
means to reduce serum cholesterol are being actively
searched for to reduce the burden of cardiovascular dis-
ease on population levels [3]. Plant stanols and sterols* Correspondence: kirsi.laitinen@raisio.com
1Benecol Division, Raisio Group, Raisio, Finland
Full list of author information is available at the end of the article
© 2012 Laitinen and Gylling.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium(phytosterols) are a group of compounds that are found
in plant-based foods like cereals and vegetable oils.
Structurally they resemble cholesterol, but they exert
much lower absorption rates compared to cholesterol.
Plant stanols and sterols have been shown to reduce
serum levels of cholesterol by partly blocking the choles-
terol absorption in the digestive tract [4].
Plant sterols and stanols are typically esterified to vege-
table oil fatty acids to ease the formulation of food applica-
tions and to ensure the cholesterol lowering effect in a wide
range of food products. Plant stanols are saturated forms ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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based ingredients used in commercial foods; plant stanol
ester that is based almost exclusively on plant stanols, i.e.
sitostanol and campestanol and plant sterol ester, that is
mainly based on plant sterols (sitosterol and campesterol).
Indeed, it has been shown in several randomized, double
blinded clinical studies that consumption of foods like
margarine or yoghurt type drink with added plant stanol
ester effectively reduce serum total cholesterol and LDL-C.
The Scientific Panel on Dietetic Products, Nutrition and
Allergies to the European Commission stated in its evalu-
ation report: “On the basis of the data presented, a clinic-
ally significant LDL-C lowering effect of about 10% can be
achieved by a daily intake of plant stanol esters equivalent
to 2 g of plant stanols in an appropriate food (e.g. fat-based
foods and low-fat foods such as yoghurt), preferably with
meals”. The Panel considers that such a reduction is of bio-
logical significance in terms of reduced risk of coronary
heart disease [5]. Meta-analyses, in which either no or only
a few large-dose studies were available or in which the
plant sterol and stanol studies were analysed together, have
arrived at similar conclusions that no added benefit is
achievable by consuming phytosterols (i.e. plant sterols or
plant stanols) in excess of about 2,5 g / day [6-8]. However,
Musa-Veloso and co-workers [9] separately studied the
dose-range effect of plant sterols and stanols on serum
LDL-C lowering and reported that plant stanols showed a
continuous dose–response in serum LDL-C lowering,
whereas no further serum LDL-C was apparent with plant
sterols at daily intakes exceeding 2 g/day.
Recently published studies conducted with larger
doses of plants stanols suggest that a further benefit to
blood lipid values may be achieved by higher daily
intakes of plant stanols. The aim of the present review is
to discuss the evidence for a dose-effect relationship be-
tween plant stanol ester consumption and reduced
serum LDL-C concentrations with daily intake exceeding
the currently recommended 2 g per day of plant stanols.
A dose response effect between plant stanol
consumption and serum LDL-C concentration
The scientific evidence for the cholesterol and LDL-C
lowering effect of plant stanol ester consumption in
amounts 2 to 3 g plant stanols per day is sound and is
supported by numerous human clinical intervention trials.
There is increasing evidence that higher daily intakes may
result in a greater serum LDL-C lowering effect and that
the dose–response relation is linear over a wider range of
intake than earlier recognized. We are now examining the
studies in which plant stanols have been consumed in
doses of 4 g or more. We could identify five such studies
from literature search [10-14]. One of the studies has been
presented only as a conference-proceedings with limited
available data on study conductance [10].An overview of the study designs and subject charac-
teristics is presented in Table 1. Four of the studies were
of high scientific quality as the studies were placebo-
controlled, randomized studies, one with cross-over de-
sign [12] and three with parallel design [11,13,14]. One
study investigated the dose–response effect of consum-
ing plant stanols in an open label study with three study
groups where the comparison of the dose–response ef-
fect was conducted with respect to the baseline levels,
but no control group was included in the study [10].
One of the studies enrolled only eight subjects, but the
study was nevertheless of sufficient statistical power to
demonstrate an LDL-C lowering effect by plant stanols
[12]. The interventions lasted from 2 to 10 weeks, which
is a sufficient time period to induce the plant stanol
ester specific blood cholesterol lowering effect [15]. The
studies were conducted with mildly hypercholesterolae-
mic, slightly overweight adults, except one study which
was conducted with normal weight, normocholesterolae-
mic adults.
The effect of plant stanol ester consumption in lowering
LDL-C concentration in the five studies is presented in
Figure 1. The dose–response relationship between plant
stanol dose (g/day) and LDL-C change (%) was tested using
the least-squares linear regression. All studies and doses
were equally weighted. The dose–response is described by
the following equation: LDL-C change (%) = −9.02 – 0.91 ×
dose (r2=0.66, p=0.001). The dose–response effect is shown
by a higher proportional decrease in LDL-C concentration
as a response to an increasing dose of plant stanol con-
sumption. The most prominent effect in LDL-C lowering
was demonstrated by doses 9 to 10 g of plant stanols. The
highest doses of plant stanol esters resulted in a reduction
of LDL-C by about 18%. A previous meta-analysis by
Musa-Veloso and co-workers [9] with partially the same
studies, demonstrated an LDL-C lowering efficacy by
plant stanols over a continuous dose range from 0.45 g to
9 g/day. From this report, the predicted dose–response re-
lationship between plant stanol dose (g/day) and LDL-C
change (%), estimated according to equation for predicted
relative change in LDL-C with weighted analysis and no
dose restriction, is depicted in Figure 2.
Scientific support for a dose-dependent serum LDL-C
lowering with plant stanol ester
Plant stanols reduce the absorption of both cholesterol
and plant sterols such as sitosterol and campesterol in
the gastrointestinal tract with a subsequent serum
cholesterol and plant sterol lowering effect. Serum
levels of plant sterols is a validated marker of choles-
terol absorption efficiency [16], although some caution
has been raised against the validity of this marker
under all circumstances [17]. In clinical studies with
plant stanol ester, the reduction in cholesterol absorption
Table 1 Characteristics of studies investigating LDL-cholesterol lowering effect of plant stanols consumption in doses of 4 g or more
Reference Subject
characteristics
Treatment characteristics
N Age (years) Men (%) weight status Baseline bloodcholesterol Study design Vehicle Dose of plant
stanols (g/d)1
Duration (wk)
[10]Nguyen 1999 83 49 30 mildly hypercholesterolaemic open label, dose-response
in comparison to
respective baselines
margarine, soya yoghurt 3 / 6 / 10 2
[11]Plat & Mensink 2000 112 33 37 normal normocholesterolaemic parallel, randomized, double-blind,
placebo-controlled
margarine, shortening
for baking
0 / 3.82 / 43 8
[12]Cater et al. 2005 8 58 75 slightly
overweight
mildly hypercholesterolaemic cross-over,randomized, double-blind,
placebo-controlled
margarine 0 / 2 / 3 / 4 6
[13]Gylling et al. 2010 49 62 35 slightly
overweight
mildly hypercholesterolaemic parallel, randomized, double-blind,
placebo-controlled
margarine,
oat based drink
0 / 8.8 10
[14]Mensink et al. 2010 93 56 53 slightly
overweight
mildly hypercholesterolaemic parallel, randomized, double-blind,
placebo-controlled
margarine,
soya based yoghurt
0 / 3 / 6 / 9 4
1 in each study group, 2vegetable oil based plant stanols, 3 pine wood based plant stanol.
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Figure 1 Dose-effect relationship between plant stanol dose
and LDL-C change (%) in five studies with plant stanol doses
between 2 to 10 g/day. Regression line (continuous line) and 95%
confidence interval (dotted lines) were calculated using the least-
squares linear regression. r2=0.66, p=0.001.
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plant sterols from the baseline to the end of the plant stanol
ester intervention. Miettinen and co-workers [18] showed
that the higher the daily consumption of sitostanol, the
bigger the reduction in serum cholesterol. The research
group also recorded a significant association between
the reduction in serum cholesterol levels and changes in
serum campesterol concentrations due to sitostanol esterFigure 2 Predicted dose-effect relationship between plant stanol dos
(predicted relative change in LDL-cholesterol, weighted analysis, no dconsumption. A similar association between the reduction
in serum/plasma campesterol and sitostanol (3 g/day)
intake was recorded a couple of years later by Gylling et al.
[19]. The recorded 15% reduction in serum LDL-C in the
intervention group versus the control group resulted in
44.5% reduction in fractional cholesterol absorption from
the gastrointestinal tract. Considering serum plant sterol
levels, the measured relative reduction in serum campes-
terol and sitosterol levels were 41.7% and 29.6%,
respectively.
Three of the studies with high daily plant stanol in-
take also reported serum plant stanol and sterol con-
centrations. Gylling and co-workers [13] demonstrated
that a daily intake of 8.8 g plant stanols decreased chol-
esterol absorption markers (serum plant sterol to chol-
esterol ratios) by up to 62%, the mean proportional
change from the baseline being 44.9 for campesterol
and 46.2 for sitosterol. Similarly, Mensink and co-
workers [14] showed continuous decrease in plasma
sitosterol and campesterol concentrations with 3, 6 and
9 g intakes of plant stanols in comparison to controls,
although the difference in changes for the 6-g and 9-g
groups were not statistically significantly different from
the previous dose. With increasing plant stanol intake,
the cholesterol absorption was reduced [14]. Nguyen
[10] reported a 40% lower campesterol and 50% lower
sitosterol levels after daily consumption of 10 g of plant
stanols.
The decrease in the LDL-C level by 18% due to con-
sumption of plant stanols in high doses (about 9 g)
is of similar magnitude to that achieved by drugse (g/day) and LDL-C change (%) estimated according to equation
ose restriction) by Musa-Veloso et al. 2011.
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sorption. Ezetimibe is a drug that reduces the uptake of
both cholesterol and plant sterols by its action on the
Nieman-Pick C1-Like1 (NPC1L1) transporter protein. A
daily dose of 10 mg ezetimibe reduces serum LDL-C
levels by some 17 – 22% versus controls [20]. Sudhop
and co-workers [21] recorded a 20.4% reduction in
serum LDL-C from baseline with ezetimibe 10 mg/day.
Fractional cholesterol absorption was reduced by 54.4%
and circulating levels of campesterol and sitosterol were
reduced by 48% and 41% respectively.
Thus, the higher relative reduction in serum plant
sterol levels obtained with higher daily intake of plant
stanols supports the notion that a higher daily intake of
plant stanols results in enhanced inhibition of choles-
terol absorption and further serum LDL-C reduction
with increasing daily intakes of plant stanols.
Consumption of plant stanol esters in doses of up to 10 g
per day is safe and feasible
Plant stanols are generally considered safe as they are
absorbed within the gastrointestinal tract only in minus-
cule quantities [22]. None of the clinical studies with
daily intakes up to 10 g of plant stanols reported any
side effects or changes in clinical characteristics like
blood pressure or indicators of liver or kidney function
or blood coagulation [11,13,14].
The 0.04 to 0.2% of the consumed plant stanol dose is
absorbed from the gastrointestinal tract. Subsequently
the circulating sitostanol concentration is raised from
the typical natural concentrations of 10–15 μg/dl to 20–
30 μg/dl. At higher intakes of 8.8 g/day of plant stanols,
the serum sitostanol levels have been demonstrated to
double from baseline level of 17 ug/dl and campesterol
levels to increase from non-detectable levels to 9 ug/dl
but to remain at a comparable level as with the lower in-
take of 2 to 3 g/day [13]. Further, the levels normalize in
four weeks after cessation of the consumption [13]. In
the study by Mensink and co-workers [14] a gradual in-
crease for plasma plant stanols was detected with in-
creasing plant stanol consumption from 3 to 6 to 9 g/
day, but again the effects were leveling off at higher
intakes. Thus whilst reducing effectively serum choles-
terol and plant sterol levels, high intakes of plant stanols
do not appear to increase the systemic availability of
plant stanols more than lower doses and appear not to
influence cognitive function [23].
A concern over plant stanol consumption has been
directed at a potential decrease in the serum concentra-
tions of lipid-soluble antioxidants and vitamins. Such
decreases in the concentrations of serum β-carotene, α-
tocopherol and lutein [14] and also α-carotene [13] by a
few percent have indeed been detected in some studies.
The observed phenomena is partly due to a reduction incirculating lipoprotein particles, the carriers of antioxi-
dants, and when the anti-oxidant concentrations are
standardized for total or LDL-C, the differences between
controls and those consuming plant stanols are minor
or non-existing [14]. Furthermore, the serum concentra-
tions of vitamins, although having decreased somewhat,
have been within normal reference limits. In the high-
dose study by Gylling and co-workers [13] the reduction
in serum β-carotene obtained with a 9 g daily intake of
plant stanols was similar to that recorded with a 2–3 g
daily intake of plant stanols, also carried out on a
Finnish population [24]. Similarly, Nguyen [10] demon-
strated that after 2-weeks of daily consumption of 10 g
of plant stanol, no decrease in serum β-carotene levels
was detected. No alteration in serum vitamin A [13] and
vitamin D [10,13] concentrations have been detected by
consumption of high doses of plant stanols. Further,
dietary intake of fruits and vegetables, the sources of car-
otenoids, in accordance with the recommended refer-
ence values have been demonstrated to sustain serum
carotenoid levels regardless of plant stanol consumption
[25]. Plant stanol ester consumption does not seem to
influence serum vitamin K levels [26] or blood coagula-
tion and fibrinolysis [27,11]. It has been demonstrated
that consumption of 4 g of plant stanols as ester had no
influence on clotting factor VII or on fibrinolytic param-
eter, plasminogen activator antigen response, but a ten-
dency for increase in the activity of antithrombin-111, a
potent inhibitor of coagulation, was detected [11]. It
should also be considered that plasma levels of vitamin
K reflect very recent daily intake. No clinical study with
plant stanol ester has been conducted where the daily
intake of vitamin K has been monitored to exclude po-
tential impact of variation in daily intake of vitamin K
close to blood sampling. Nevertheless, there is an obvi-
ous need for further investigation into the functional
effects of plant stanol ester consumption in high doses
on blood coagulation and fibrinolysis particularly in
patients receiving warfarin therapy.
Consumption of plant stanols in doses up to 10 g per
day is nowadays feasible as a range of food products are
available for consumption including spreads, mayonnaise,
salad dressing, yoghurt drinks and bread. Due to this vari-
ability in choice of food products the compliance of the
study subject in consuming the plant stanol containing
food has been good. The food matrix in which plant sta-
nols are incorporated does not appear to contribute to the
cholesterol lowering effect of the plant stanols [9]. The
fatty acid composition of high-fat products like spreads
with added plant stanol esters is in line with dietary
recommendations calling for an increase in consumption
of unsaturated fatty acids along with decrease in saturated
fatty acids. Consumption of such high-fat food products
with added plant stanol esters has therefore an additional
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with potentially unfavorable fatty acid composition. Fur-
ther, there are also several low-fat products like yoghurt
type drinks commercially available that do not add fat to
the diet.
Conclusions
The scientific evidence for the cholesterol and LDL-C
lowering effect as well as safety of daily consumption of
plant stanol esters is well-documented in scientific lit-
erature. The most recent progress in the area of plant
stanol research is the provision of evidence that intakes
of plant stanols in higher doses than currently recom-
mended result in an enhanced decrease in LDL-C
concentrations comparable to that obtained by pharma-
cological means. Plant stanol intakes in daily doses of 9
to 10 g results in LDL-C lowering by up to 18%. The ap-
proach for lowering LDL-C with higher (4 to 6 g) daily
intakes of plant stanols is feasible as a range of food pro-
ducts are commercially available for consumption.
Enhanced serum LDL-C lowering by 10% likely contri-
butes to beneficial effects in reducing the risk of cardio-
vascular diseases by 10% through dietary means [28].
The approach likely provides cost-effective benefit and
may be seen as an amenable public health policy [29].
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